Receptors, Tumor Necrosis Factor
"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
| Descriptor ID |
D018124
|
| MeSH Number(s) |
D12.776.543.750.705.852.760
|
| Concept/Terms |
Receptors, Tumor Necrosis Factor- Receptors, Tumor Necrosis Factor
- Receptors, Cachectin
- Tumor Necrosis Factor Receptors
- TNF Receptor
- Receptor, TNF
- TNF Receptors
- Tumor Necrosis Factor Receptor
- Cachectin Receptors
- Receptors, TNF
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".
- Receptors, Tumor Necrosis Factor
- B-Cell Activation Factor Receptor
- B-Cell Maturation Antigen
- CD40 Antigens
- Etanercept
- fas Receptor
- Glucocorticoid-Induced TNFR-Related Protein
- Ki-1 Antigen
- Lymphotoxin beta Receptor
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Ectodysplasin
- Receptors, OX40
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor, Member 14
- Receptors, Tumor Necrosis Factor, Member 25
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Transmembrane Activator and CAML Interactor Protein
- Tumor Necrosis Factor Decoy Receptors
- Tumor Necrosis Factor Receptor Superfamily, Member 7
- Tumor Necrosis Factor Receptor Superfamily, Member 9
- TWEAK Receptor
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2010 | 3 | 0 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Alimchandani M, Wang ZF, Miettinen M. CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases. Appl Immunohistochem Mol Morphol. 2014 May-Jun; 22(5):358-62.
-
Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential Fc?RIIB coengagement in vivo. Proc Natl Acad Sci U S A. 2013 Nov 26; 110(48):19501-6.
-
Bruminhent J, Lynch TK, Gefen J, Santoro J. Listeria monocytogenes cholecystitis: a possible new syndrome. Am J Med Sci. 2013 May; 345(5):414-7.
-
Li F, Ravetch JV. A general requirement for Fc?RIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle. 2012 Sep 15; 11(18):3343-4.
-
Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc? receptor engagement. Proc Natl Acad Sci U S A. 2012 Jul 03; 109(27):10966-71.
-
Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozzi L, Wajdula J, Zang C, Nelson H, Raible D. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011 Jun; 37(6):1352-9.
-
Zhou SY, Shu C, Korth-Bradley J, Raible D, Palmisano M, Wadjula J, Fatenejad S, Bjornsson T. Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol. 2011 Jun; 51(6):864-75.
-
Chapman P, Cranmer L, Dixon WG, Hyrich KL, Patterson JR, Symmons DP, Toporcer M, Mastrangelo MJ. The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol. 2010 Feb; 37(1):11-9.
-
Fain JN, Nesbit AS, Sudlow FF, Cheema P, Peeples JM, Madan AK, Tichansky DS. Release in vitro of adipsin, vascular cell adhesion molecule 1, angiotensin 1-converting enzyme, and soluble tumor necrosis factor receptor 2 by human omental adipose tissue as well as by the nonfat cells and adipocytes. Metabolism. 2007 Nov; 56(11):1583-90.
-
Fain JN, Buehrer B, Tichansky DS, Madan AK. Regulation of adiponectin release and demonstration of adiponectin mRNA as well as release by the non-fat cells of human omental adipose tissue. Int J Obes (Lond). 2008 Mar; 32(3):429-35.